Immune Checkpoint Inhibition in Locally Advanced, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma. (PubMed, Clin Dermatol) - Sep 13, 2026 - P3 | "Cemiplimab and pembrolizumab are programmed cell death 1 (PD-1) inhibitors and cosibelimab is a programmed death ligand 1 (PD-L1) inhibitor, all FDA approved for advanced cSCC...Neoadjuvant cemiplimab has generated high pathologic response rates and the randomized phase II MATISSE trial supports continued investigation of neoadjuvant nivolumab with or without ipilimumab. Despite the biologic rationale for biomarker-guided treatment, tumor mutational burden and PD-L1 expression have not shown sufficiently consistent predictable values for clinical selection. Active investigations into the efficacy of ICIs in advanced resectable and unresectable cSCC are rapidly shifting management with evidence revealing promises of greater disease-free survival through neoadjuvant and adjuvant approaches."
Checkpoint inhibition • IO biomarker • Journal • Tumor mutational burden • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation • TMB
|
|
A Maria Vromans; Bridget Harrop; Jane M Grant-Kels; Maria Constantinou; Matthew J Hadfield; Nicole Flores
|